(Q36606791)

15 August 2017

1 reference

title

The use of antiepileptic drugs in bipolar disorders: a review based on evidence from controlled trials (English)

1 reference

15 August 2017

5

Terence A Ketter

1 reference

15 August 2017

4

Robert M Post

1 reference

15 August 2017

Richard H Weisler

1

1 reference

15 August 2017

Andrew J Cutler

series ordinal

2

1 reference

15 August 2017

James C Ballenger

series ordinal

3

1 reference

15 August 2017

publication date

1 October 2006

1 reference

15 August 2017

1 reference

15 August 2017

volume

11

1 reference

15 August 2017

issue

10

1 reference

15 August 2017

page(s)

788-799

1 reference

Topiramate and divalproex in combination with risperidone for acute mania: a randomized open-label study

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900014917

Comparison of the antimanic efficacy of carbamazepine and lithium carbonate by double-blind controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900014917

A double-blind study of adjunctive carbamazepine versus placebo on excited states of schizophrenic and schizoaffective disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900014917

Comparison of the antimanic efficacy of carbamazepine and chlorpromazine: A double-blind controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900014917

Clinical predictors of response to lamotrigine and gabapentin monotherapy in refractory affective disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900014917

Olanzapine versus divalproex in the treatment of acute mania

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900014917

Maintenance therapies for classic and other forms of bipolar disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900014917

A Double-Blind, Placebo-Controlled, Prophylaxis Study of Lamotrigine in Rapid-Cycling Bipolar Disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900014917

A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900014917

Effectiveness and medical costs of divalproex versus lithium in the treatment of bipolar disorder: results of a naturalistic clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900014917

Valproate in the treatment of acute mania. A placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900014917

A double-blind comparison of valproate and lithium in the treatment of acute mania

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900014917

Efficacy of divalproex vs lithium and placebo in the treatment of mania. The Depakote Mania Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900014917

Systematic overview of lithium treatment in acute mania

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900014917

Extending indications for long-term pharmacotherapy: opportunities and challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900014917

The first open study of zonisamide, a novel anticonvulsant, shows efficacy in mania.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900014917

A placebo-controlled study of lamotrigine and gabapentin monotherapy in refractory mood disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900014917

Lamotrigine: a review of its use in bipolar disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900014917

Effect of phenytoin on mood and declarative memory during prescription corticosteroid therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900014917

Prophylactic effect of phenytoin in bipolar disorder: a controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900014917

Relapse prevention in bipolar I disorder: 18-month comparison of olanzapine plus mood stabiliser v. mood stabiliser alone

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900014917

Divalproex in the treatment of bipolar depression: a placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900014917

Service utilization and costs of olanzapine versus divalproex treatment for acute mania: results from a randomized, 47-week clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900014917

Olanzapine versus divalproex sodium for the treatment of acute mania and maintenance of remission: a 47-week study

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900014917

Quetiapine with lithium or divalproex for the treatment of bipolar mania: a randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900014917

Relationship of mania symptomatology to maintenance treatment response with divalproex, lithium, or placebo

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900014917

Efficacy of valproate maintenance in patients with bipolar disorder and alcoholism: a double-blind placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900014917

Maintenance efficacy of divalproex in the prevention of bipolar depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900014917

A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Divalproex Maintenance Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900014917

Quetiapine versus placebo in combination with lithium or divalproex for the treatment of bipolar mania

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900014917

A double-blind, randomized, placebo-controlled study of quetiapine as adjunctive treatment for adolescent mania

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900014917

Mood stabilisers plus risperidone or placebo in the treatment of acute mania. International, double-blind, randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900014917

Combination of a mood stabilizer with risperidone or haloperidol for treatment of acute mania: a double-blind, placebo-controlled comparison of efficacy and safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900014917

Quality of life assessment in patients with bipolar disorder treated with olanzapine added to lithium or valproic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900014917

Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to valproate or lithium monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900014917

A 6-month randomized, placebo-controlled, dose-ranging trial of topiramate for weight loss in obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900014917

Oral topiramate for treatment of alcohol dependence: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900014917

Topiramate versus bupropion SR when added to mood stabilizer therapy for the depressive phase of bipolar disorder: a preliminary single-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900014917

A pilot controlled trial of topiramate for mania in children and adolescents with bipolar disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900014917

Adjunctive topiramate treatment for pediatric bipolar disorder: a retrospective chart review

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900014917

A pilot study of topiramate as monotherapy in the treatment of acute mania

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900014917

The evolving role of topiramate among other mood stabilizers in the management of bipolar disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900014917

Gabapentin for the Treatment of Postherpetic Neuralgia: A Randomized Controlled Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900014917

Treatment of social phobia with gabapentin: a placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900014917

Placebo-controlled study of gabapentin treatment of panic disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900014917

Gabapentin in bipolar disorder: a placebo-controlled trial of adjunctive therapy. Gabapentin Bipolar Disorder Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900014917

Intravenous Fosphenytoin in Acute Mania

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900014917

Differential response to lithium and carbamazepine in the prophylaxis of bipolar disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900014917

7 January 2021

Lithium versus carbamazepine in the maintenance treatment of bipolar disorders--a randomised study

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900014917

7 January 2021

A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder.

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900014917

7 January 2021

An open prospective study of zonisamide in acute bipolar depression

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900014917

7 January 2021

Open-label adjunctive zonisamide in the treatment of bipolar disorders: a prospective trial.

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900014917

7 January 2021

Preliminary observations on the effectiveness of levetiracetam in the open adjunctive treatment of refractory bipolar disorder

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900014917

7 January 2021

Levetiracetam in the treatment of acute mania: an open add-on study with an on-off-on design

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900014917

7 January 2021

A double-blind, randomized, placebo-controlled trial of oxcarbazepine in the treatment of bipolar disorder in children and adolescents

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900014917

7 January 2021

The use of sodium valproate, carbamazepine and oxcarbazepine in patients with affective disorders

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900014917

7 January 2021

Extended-release carbamazepine capsules as monotherapy for acute mania in bipolar disorder: a multicenter, randomized, double-blind, placebo-controlled trial.

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900014917

7 January 2021

A multicenter, randomized, double-blind, placebo-controlled trial of extended-release carbamazepine capsules as monotherapy for bipolar disorder patients with manic or mixed episodes.

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900014917

7 January 2021

Carbamazepine in manic-depressive illness: a new treatment

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900014917

7 January 2021

Correlates of antimanic response to carbamazepine

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900014917

7 January 2021

A 7-week, randomized, double-blind trial of olanzapine/fluoxetine combination versus lamotrigine in the treatment of bipolar I depression.

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900014917

7 January 2021

A Double-Blind, Randomized, Placebo-Controlled Trial of Augmentation With Lamotrigine or Placebo in Patients Concomitantly Treated With Fluoxetine for Resistant Major Depressive Episodes

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900014917

7 January 2021

A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Lamictal 602 Study Group.

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900014917

7 January 2021

Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: consensus and controversies

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900014917

7 January 2021

The Texas implementation of medication algorithms: update to the algorithms for treatment of bipolar I disorder.

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900014917

7 January 2021

Antimanic Efficacy of Topiramate in 11 Patients in an Open Trial With an On-Off-On Design

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900014917

7 January 2021

A double-blind, randomized, placebo-controlled, prophylaxis study of adjunctive gabapentin for bipolar disorder.

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900014917

7 January 2021

Antidepressant effects of carbamazepine

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900014917

7 January 2021

Risperidone in combination with mood stabilizers: a 10-week continuation phase study in bipolar I disorder.

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900014917

7 January 2021

Topiramate as add-on treatment for patients with bipolar mania

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900014917

7 January 2021

Outcome in manic disorders. A naturalistic follow-up study

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900014917

7 January 2021

Comparative prophylactic efficacy of lithium, carbamazepine, and the combination in bipolar disorder.

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900014917

7 January 2021

A comparison of the efficacy, safety, and tolerability of divalproex sodium and olanzapine in the treatment of bipolar disorder

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900014917

7 January 2021

A Preliminary Open-Label Study of Zonisamide Treatment for Bipolar Depression in 10 Patients

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900014917

7 January 2021

Long-term combination therapy versus monotherapy with lithium and carbamazepine in 46 bipolar I patients.

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900014917

7 January 2021

Efficacy of lithium prophylaxis in clinical practice

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900014917

7 January 2021

Topiramate monotherapy in the management of acute mania: results of four double-blind placebo-controlled trials

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900014917

7 January 2021

Does maintenance lithium therapy prevent recurrences of mania under ordinary clinical conditions?

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900014917

7 January 2021

Carbamazepine compared with lithium in the treatment of mania

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900014917

7 January 2021

10.1017/S1092852900014917

Identifiers

DOI

1 reference

15 August 2017

1 reference